Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment

Cancer Treatment Reviews

Volumn 45, Issue , 2016, Pages 19-29

  Ngamcherdtrakul, Worapol ^a,b   Castro, David J ^a,b   Gu, Shenda ^a   Morry, Jingga ^a   Reda, Moataz ^a   Gray, Joe W ^a   Yantasee, Wassana ^a,b  

^a Oregon Health and Science University Department of Biomedical Engineering   (United States)

^b PDX Pharmaceuticals LLC   (United States)

Author keywords

Breast cancer; Nanoparticle; Oligonucleotide; SiRNA; Targeted delivery; Targeted therapy

Indexed keywords

ALN VSP02; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APTAMER; ATU 027; CALAA 01; CALCIUM PHOSPHATE NANOPARTICLE; CARBON NANOTUBE; CYCLODEXTRIN; DCR MYC; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GOLD NANOPARTICLE; LIPOSOME; MESOPOROUS SILICA NANOPARTICLE; MICRORNA; NANOPARTICLE; OLIGONUCLEOTIDE; PACLITAXEL; PERTUZUMAB; QUANTUM DOT; RIBOZYME; SIRNA EPHA2 DOPC; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TKM 080301; TRASTUZUMAB; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN;

ACUTE TOXICITY; BREAST CANCER; CANCER THERAPY; CHRONIC TOXICITY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; HER2 POSITIVE BREAST CANCER; HUMAN; MOLECULARLY TARGETED THERAPY; REVIEW; THERAPY RESISTANCE; TRANSLATIONAL RESEARCH; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; PROCEDURES; RNAI THERAPEUTICS;

ADMINISTRATION, INTRAVENOUS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; NANOPARTICLES; OLIGONUCLEOTIDES; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; RNAI THERAPEUTICS;

EID: 84959251161     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.02.005     Document Type: Review

References (100)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
2. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
3. Rana T.M. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007, 8:23-36.
4. Burnett J.C., Rossi J.J. RNA-based therapeutics - current progress and future prospects. Chem Biol 2012, 19:60-71.
5. Gomes-da-Silva L.C., Simoes S., Moreira J.N. Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology. Cell Mol Life Sci 2014, 71:1417-1438.
6. Bramsen J.B., Laursen M.B., Nielsen A.F., Hansen T.B., Bus C., Langkjaer N., et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 2009, 37:2867-2881.
7. Dong H., Lei J., Ding L., Wen Y., Ju H., Zhang X. MicroRNA: function, detection, and bioanalysis. Chem Rev 2013, 113:6207-6233.
8. Zhang B., Pan X., Cobb G.P., Anderson T.A. MicroRNAs as oncogenes and tumor suppressors. Develop Biol 2007, 302:1-12.
9. Daige C.L., Wiggins J.F., Priddy L., Nelligan-Davis T., Zhao J., Brown D. Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer. Mol Cancer Ther 2014, 13:2352-2360.
10. Eckstein F. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?. Antisense Nucleic Acid Drug Dev 2000, 10:117-121.
11. Bijsterbosch M.K., Manoharan M., Rump E.T., De Vrueh R.L., van Veghel R., Tivel K.L., et al. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res 1997, 25:3290-3296.
12. Bennett C.F., Swayze E.E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010, 50:259-293.
13. Herbst R.S., Frankel S.R. Oblimersen sodium (genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 2004, 10:4245s-4248s.
14. Frantz S. Lessons learnt from Genasense's failure. Nat Rev Drug Discov 2004, 3:542.
15. Inman S. Custirsen combination misses goal in phase III mCRPC trial. OncLive. Plainsboro, NJ; 2014.
16. Chiarle R., Simmons W.J., Cai H., Dhall G., Zamo A., Raz R., et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005, 11:623-629.
17. Yamamoto Y., Loriot Y., Beraldi E., Zhang F., Wyatt A.W., Nakouzi A.L., et al. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide resistant prostate cancer cell growth. Clin Cancer Res 2015.
18. Hong D., Kim Y., Younes A., Nemunaitis J., Fowler N., Hsu J., et al. Abstract LB-227: preclinical pharmacology and clinical efficacy of AZD9150 (ISIS-STAT3Rx), a potent next-generation antisense oligonucleotide inhibitor of STAT3. Cancer Res 2014, 74:LB-227.
19. Weng D.E., Masci P.A., Radka S.F., Jackson T.E., Weiss P.A., Ganapathi R., et al. A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol Cancer Ther 2005, 4:948-955.
20. Morrow P.K., Murthy R.K., Ensor J.D., Gordon G.S., Margolin K.A., Elias A.D., et al. An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. Cancer 2012, 118:4098-4104.
21. Rayburn E.R., Zhang R. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?. Drug Discovery Today 2008, 13:513-521.
22. Rosenberg J.E., Bambury R.M., Van Allen E.M., Drabkin H.A., Lara P.N., Harzstark A.L., et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs 2014, 32:178-187.
23. Hickerson R.P., Vlassov A.V., Wang Q., Leake D., Ilves H., Gonzalez-Gonzalez E., et al. Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 2008, 18:345-354.
24. Bramsen J.B., Laursen M.B., Nielsen A.F., Hansen T.B., Bus C., Langkjær N., et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 2009.
25. Pascut D., Bedogni G., Tiribelli C. Silencing efficacy prediction: a retrospective study on target mRNA features. Biosci Rep 2015, 35:e00185.
26. Sinn P.L., Sauter S.L., McCray P.B. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther 2005, 12:1089-1098.
27. Deng Z.J., Morton S.W., Ben-Akiva E., Dreaden E.C., Shopsowitz K.E., Hammond P.T. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano 2013, 7:9571-9584.
28. Song E., Zhu P., Lee S.-K., Chowdhury D., Kussman S., Dykxhoorn D.M., et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005, 23:709-717.
29. Nel A.E., Madler L., Velegol D., Xia T., Hoek E.M.V., Somasundaran P., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8:543-557.
30. Dobrovolskaia M.A., Aggarwal P., Hall J.B., McNeil S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008, 5:487-495.
31. Otsuka H., Nagasaki Y., Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 2003, 55:403-419.
32. Salmaso S., Caliceti P. Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv 2013, 2013:19.
33. Knudsen K.B., Northeved H., Kumar Ek P., Permin A., Gjetting T., Andresen T.L., et al. In vivo toxicity of cationic micelles and liposomes. Nanomed Nanotechnol Biol Med 2015, 11:467-477.
34. Fischer D., Li Y., Ahlemeyer B., Krieglstein J., Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003, 24:1121-1131.
35. O'Mahony A.M., Ogier J., Darcy R., Cryan J.F., O'Driscoll C.M. Cationic and PEGylated amphiphilic cyclodextrins: co-formulation opportunities for neuronal sirna delivery. PLoS ONE 2013, 8:e66413.
36. Ngamcherdtrakul W., Morry J., Gu S., Castro D.J., Goodyear S.M., Sangvanich T., et al. Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER2+ breast cancer. Adv Funct Mater 2015, 25:2646-2659.
37. Gabrielson N.P., Lu H., Yin L., Kim K.H., Cheng J. A cell-penetrating helical polymer for siRNA delivery to mammalian cells. Mol Ther 2012, 20:1599-1609.
38. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
39. Bertrand N., Wu J., Xu X., Kamaly N., Farokhzad O.C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014, 66:2-25.
40. Harrington K.J., Mohammadtaghi S., Uster P.S., Glass D., Peters A.M., Vile R.G., et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001, 7:243-254.
41. Davis M.E., Zuckerman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
42. Tabernero J., Shapiro G.I., LoRusso P.M., Cervantes A., Schwartz G.K., Weiss G.J., et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013, 3:406-417.
43. Prabhakar U., Maeda H., Jain R.K., Sevick-Muraca E.M., Zamboni W., Farokhzad O.C., et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013, 73:2412-2417.
44. Toporkiewicz M., Meissner J., Matusewicz L., Czogalla A., Sikorski A.F. Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int J Nanomed 2015, 10:1399-1414.
45. Li S.-D., Chen Y.-C., Hackett M.J., Huang L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 2007, 16:163-169.
46. Seib F.P., Jones A.T., Duncan R. Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells. J Control Release 2007, 117:291-300.
47. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010, 188:759-768.
48. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520.
49. Dominska M., Dykxhoorn D.M. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 2010, 123:1183-1189.
50. Xu Y., Szoka F.C. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996, 35:5616-5623.
51. Tam Y.Y.C., Chen S., Cullis P.R. Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics 2013, 5:498-507.
52. Lorenzer C., Dirin M., Winkler A.M., Baumann V., Winkler J. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release 2015, 203:1-15.
53. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009, 6:659-668.
54. Vader P., van der Aa L.J., Storm G., Schiffelers R.M., Engbersen J.F. Polymeric carrier systems for siRNA delivery. Curr Top Med Chem 2012, 12:108-119.
55. Hayashi K., Nakamura M., Sakamoto W., Yogo T., Miki H., Ozaki S., et al. Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment. Theranostics 2013, 3:366-376.
56. Resch-Genger U., Grabolle M., Cavaliere-Jaricot S., Nitschke R., Nann T. Quantum dots versus organic dyes as fluorescent labels. Nat Methods 2008, 5:763-775.
57. Austin L.A., Mackey M.A., Dreaden E.C., El-Sayed M.A. The optical, photothermal, and facile surface chemical properties of gold and silver nanoparticles in biodiagnostics, therapy, and drug delivery. Arch Toxicol 2014, 88:1391-1417.
58. Morry J., Ngamcherdtrakul W., Gu S., Goodyear S.M., Castro D.J., Reda M.M., et al. Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis. Biomaterials 2015, 66:41-52.
59. Zhang X. Gold nanoparticles: recent advances in the biomedical applications. Cell Biochem Biophys 2015.
60. Ehlerding E.B., Chen F., Cai W. Biodegradable and renal clearable inorganic nanoparticles. Adv Sci 2016, 3.
61. Li J., Chen Y.-C., Tseng Y.-C., Huang L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release 2010, 142:416-421.
62. Tarn D., Ashley C.E., Xue M., Carnes E.C., Zink J.I., Brinker C.J. Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. Acc Chem Res 2013, 46:792-801.
63. Chung T.H., Wu S.H., Yao M., Lu C.W., Lin Y.S., Hung Y., et al. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials 2007, 28:2959-2966.
64. Phillips E., Penate-Medina O., Zanzonico P.B., Carvajal R.D., Mohan P., Ye Y., et al. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci Transl Med 2014, 6:260ra149.
65. Shen J., Kim H.C., Su H., Wang F., Wolfram J., Kirui D., et al. Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics. Theranostics 2014, 4:487-497.
66. Lin D., Cheng Q., Jiang Q., Huang Y., Yang Z., Han S., et al. Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo. Nanoscale 2013, 5:4291-4301.
67. Meng H., Mai W.X., Zhang H., Xue M., Xia T., Lin S., et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 2013, 7:994-1005.
68. Chertok B., Moffat B.A., David A.E., Yu F., Bergemann C., Ross B.D., et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008, 29:487-496.
69. Wu C., Gong F., Pang P., Shen M., Zhu K., Cheng D., et al. An RGD-modified MRI-visible polymeric vector for targeted siRNA delivery to hepatocellular carcinoma in nude mice. PLoS ONE 2013, 8:e66416.
70. Yang Y., Hu Y., Wang Y., Li J., Liu F., Huang L. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung caner. Mol Pharm 2012, 9:2280-2289.
71. Jensen S.A., Day E.S., Ko C.H., Hurley L.A., Luciano J.P., Kouri F.M., et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med 2013, 5.
72. Liu Y., Zhao Y., Sun B., Chen C. Understanding the toxicity of carbon nanotubes. Acc Chem Res 2013, 46:702-713.
73. Podesta J.E., Al-Jamal K.T., Herrero M.A., Tian B., Ali-Boucetta H., Hegde V., et al. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 2009, 5:1176-1185. (Weinheim an der Bergstrasse, Germany).
74. Nguyen K.C., Rippstein P., Tayabali A.F., Willmore W.G. Mitochondrial toxicity of cadmium telluride quantum dot nanoparticles in mammalian hepatocytes. Toxicol Sci 2015, 146:31-42.
75. Lin G., Ouyang Q., Hu R., Ding Z., Tian J., Yin F., et al. In vivo toxicity assessment of non-cadmium quantum dots in BALB/c mice. Nanomedicine 2015, 11:341-350.
76. Molitoris B.A., Dagher P.C., Sandoval R.M., Campos S.B., Ashush H., Fridman E., et al. SiRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009, 20:1754-1764.
77. Zuckerman J.E., Gritli I., Tolcher A., Heidel J.D., Lim D., Morgan R., et al. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci 2014, 111:11449-11454.
78. Zuckerman J.E., Choi C.H.J., Han H., Davis M.E. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci 2012, 109:3137-3142.
79. Aleku M., Schulz P., Keil O., Santel A., Schaeper U., Dieckhoff B., et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 2008, 68:9788-9798.
80. Schultheis B., Strumberg D., Santel A., Vank C., Gebhardt F., Keil O., et al. First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol 2014, 32:4141-4148.
81. Ramanathan R.K., Hamburg S.I., Borad M.J., Seetharam M., Kundranda M.N., Lee P., et al. A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors. AACR 104th annual meeting 2013, Washington, DC.
82. Dudek H., Wong D.H., Arvan R., Shah A., Wortham K., Ying B., et al. Knockdown of [beta]-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo. Mol Ther 2014, 22:92-101.
83. Tolcher A.W., Papadopoulos K.P., Patnaik A., Rasco D.W., Martinez D., Wood D.L. Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors. ASCO annual meeting 2015 2015.
84. Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005, 65:6910-6918.
85. Zuckerman J.E., Davis M.E. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov 2015, 14:843-856.
86. ACS Cancer facts & figures 2015 2015, American Cancer Society, Atlanta.
87. Nassar A., Khoor A., Radhakrishnan R., Radhakrishnan A., Cohen C. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas. Int J Clin Exp Pathol 2014, 7:6254-6261.
88. Prat A., Carey L.A., Adamo B., Vidal M., Tabernero J., Cortes J., et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst 2014, 106.
89. Alvarez R.H., Cortés J., Mattos-Arruda L.D., Falzon M., Fasolo A., Gandy M., et al. Handbook of HER2-targeted agents in breast cancer 2013, Springer Healthcare Communications, London, UK.
90. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847.
91. Gu S, Hu Z, Ngamcherdtrakul W, Castro DJ, Morry J, Reda MM, et al. Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget, in press. http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget%26page=article%26op=view%26path[]=7409.
92. Inoue S., Ding H., Portilla-Arias J., Hu J., Konda B., Fujita M., et al. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res 2011, 71:1454-1464.
93. Degenhardt Y., Lampkin T. Targeting polo-like kinase in cancer therapy. Clin Cancer Res 2010, 16:384-389.
94. Yao Y.D., Sun T.M., Huang S.Y., Dou S., Lin L., Chen J.N., et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med 2012, 4:130ra48.
95. Dou S., Yang X.Z., Xiong M.H., Sun C.Y., Yao Y.D., Zhu Y.H., et al. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2(+) breast cancer. Adv Health Mater 2014, 3:1792-1803.
96. Yu T., Greish K., McGill L.D., Ray A., Ghandehari H. Influence of geometry, porosity, and surface characteristics of silica nanoparticles on acute toxicity: their vasculature effect and tolerance threshold. ACS Nano 2012, 6:2289-2301.
97. Chen Y., Chen H., Shi J. In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv Mater 2013, 25:3144-3176.
98. Shi Y., Miller M.L., Di Pasqua A.J. Biocompatibility of mesoporous silica nanoparticles?. Comments Inorg Chem 2016, 36:61-80.
99. He Q., Zhang J., Shi J., Zhu Z., Zhang L., Bu W., et al. The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses. Biomaterials 2010, 31:1085-1092.
100. Isaac O.-J., Olivia T., Julia L., Victor F.P. Engineered nonviral nanocarriers for intracellular gene delivery applications. Biomed Mater 2012, 7. 054106.